Comorbidities in heart failure: A key issue

European Journal of Heart Failure, Supplement

Volumn 8, Issue SUPPL. 1, 2009, Pages

  Angermann, C E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ANEMIA; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMORBIDITY; DEPRESSION; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; KIDNEY DISEASE; MEDICARE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 77949577786     PISSN: 15674215     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp009     Document Type: Review

References (29)

1. Angermann CE, Gelbrich G, Störk S et al. On behalf of the MOOD-HF Investi-gators. Rationale and design of a randomised, controlled, multicenter trial inves-tigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail 2007;9:1212-1222.
2. Anker SD, Doehner W, Rauchhaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-1997.
3. Braunstein JB, Anderson GF, Gerstenblith G et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42:1226-1233.
4. Brown AM, Cleland JG. Influence of concomitant disease on patterns of hospital-ization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J 1998;19:163-169.
5. Charlson M, Charlson RE, Briggs W, Hollenberg J. Can disease management target patients most likely to generate high costs? The impact of comorbidity. J Gen Intern Med 2007;22:464-469.
6. Faller H, Störk S, Schowalter M et al. Depression and survival in chronic heart failure: does gender play a role? Eur J Heart Fail 2007;9:1018-1023.
7. Hasdai D, Topol EJ, Kilaru R et al. Frequency, patient characteristics, and out-comes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J 2003;145:73-79.
8. Horwich TB, Fonarow GC. Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS. Semin Dial 2007;20:549-553.
9. Jiang W, Kuchibhatla M, Clary GL et al. Relationship between depressive symp-toms and long-term mortality in patients with heart failure. Am Heart J 2007; 154:102-108.
10. Kalantar-Zadeh K, Horwich TB, Oreopoulos A et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 2007;10:433-442.
11. Kamalesh M. Heart failure in diabetes and related conditions. J Card Fail 2007;13: 861-873.
12. Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000;38:504-513.
13. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007;49:171-180.
14. Levy WC, Mozaffarian D, Linker DT et al. The Seattle Heart Failure Model: pre-diction of survival in heart failure. Circulation 2006;113:1424-1433.
15. Maier SF. Bidirectional immune-brain communication: Implications for under-standing stress, pain, and cognition. Brain Behav Immun 2003;17:69-85.
16. Masoudi FA, Havranek EP, Wolfe P et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003;146: 250-257.
17. Obialo CI. Cardiorenal consideration as a riskfactorfor heart failure. Am J Cardiol 2007;99(6B):21D-24D.
18. Rathore SS, Masoudi FA, Wang Y et al. Socioeconomic status, treatment, and out-comes among elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. Am Heart J 2006;152:371-378.
19. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998;19:1516-1520.
20. Rugulies R. Depression as a predictor for coronary heart disease. a review and meta-analysis. Am J PrevMed 2002;23:51-61.
21. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure. A meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006;48:1527-1537.
22. Rutten FH, Cramer MJ, LammersJW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail 2006;8:706-711.
23. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85-97.
24. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006; 26:296-306.
25. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for car-diovascular morbidity and mortality. Proc Am Thorac Soc 2005;2:8-11.
26. Störk S, Hense W, Zehntgraf C et al. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure. A prospective cohort study. Eur J Heart Fail 2008;10:1236-1245.
27. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454-2461.
28. Verdecchia P, Angeli F, Achilli P et al. Echocardiographic left ventricular hypertro-phy in hypertension: marker for future events or mediator of events? Curr Opin Cardiol 2007;22:329-334.
29. Yndestad A, Damas JK, Øie E, Ueland T, Gullestad L, Aukrust P. Role of inflammation in the progression of heart failure. Curr Cardiol Rep 2007;9:236-241.